The DECIDE CGM study, sponsored by Ohio State University, aimed to evaluate the effectiveness of Continuous Glucose Monitoring (CGM) in managing gestational diabetes treated with Metformin compared to Insulin. The study's withdrawal indicates a strategic focus on the parent DECIDE trial, which may impact the development of CGM technologies in this therapeutic area. The market for diabetes management, particularly in pregnancy, remains competitive with significant players like Dexcom, Inc. and Abbott Laboratories. The findings from the parent trial could influence treatment protocols and market positioning for both Metformin and Insulin in GDM management, as well as CGM device adoption in clinical practice.